Your browser doesn't support javascript.
loading
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.
Juat, Damie J; Hachey, Stephanie J; Billimek, John; Del Rosario, Michael P; Nelson, Edward L; Hughes, Christopher C W; Zell, Jason A.
Afiliação
  • Juat DJ; Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, USA.
  • Hachey SJ; Department of Family Medicine, University of California Irvine, Irvine, CA, USA.
  • Billimek J; Department of Family Medicine, University of California Irvine, Irvine, CA, USA.
  • Del Rosario MP; Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.
  • Nelson EL; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
  • Hughes CCW; Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, USA.
  • Zell JA; Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.
Oncologist ; 27(3): 210-219, 2022 03 11.
Article em En | MEDLINE | ID: mdl-35274719
ABSTRACT
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. For the vast majority of patients with advanced CRC (ie, for those in whom metastatic tumors are unresectable), treatment is palliative and typically involves chemotherapy, biologic therapy, and/or immune checkpoint inhibition. In recent years, the use of adoptive T-cell therapy (ACT), leveraging the body's own immune system to recognize and target cancer, has become increasingly popular. Unfortunately, while ACT has been successful in the treatment of hematological malignancies, it is less efficacious in advanced CRC due in part to a lack of productive immune infiltrate. This systematic review was conducted to summarize the current data for the efficacy and safety of ACT in advanced CRC. We report that ACT is well tolerated in patients with advanced CRC. Favorable survival estimates among patients with advanced CRC receiving ACT demonstrate promise for this novel treatment paradigm. However, additional stage I/II clinical trials are needed to establish the efficacy and safety of ACT in patients with CRC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Imunoterapia Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Imunoterapia Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article